In our current studies (Fig. 4) , we saw transient phosphorylation of Akt occurring 1-6 h after matrix release. In order to determine whether we were obtaining results that conflicted with published data, we assessed phosphorylation of Akt at later time points (up to 48 h) after release (i.e., we repeated a previously-published experiment). As shown in these panels, the phosphorylation of Akt did not show significant change during the 48 h observation period in attached FPCM. In the released FPCM, a rapid and transient phosphorylation of Akt was detected, beginning at 1 h (consistent with Fig. 4 ). At the 12 h time point, however, Akt phosphorylation in the released matrix decreased relative to the attached matrix, which was consistent with previously-published data. Tian et al., 2002; Xia et al., 2004) (C-F) Effect of kinase inhibitors on phosphorylation of the target kinases. In order to demonstrate that the dose of each kinase inhibitor that was utilized was adequate to suppress kinase activity, attached FPCMs were pretreated with two doses of each kinase inhibitor (SB203580 in panel C, SP600125 in panel D, U0126 in panel E, and LY294002 in panel F), and then immunoblotting for the respective phospho-proteins of target kinases was performed 30 min after matrix release. With inhibitor pretreatment, reduction of kinase phosphorylation after matrix release was complete or near-complete for p38, ERK and Akt, and ~80% complete for JNK.
Supplementary Fig. S3. Effect of FPCM release on Akt phosphorylation (48 h time course).
(A-B) Effect of pharmacological inhibition of MAP kinases or Akt on fibroblast migration out of the attached FPCM. The experiment shown in this panel was intended as a control experiment for the data shown in Fig. 5E -F, in which only data from the nested released matrix were shown.
In Supplementary Fig. S3A , an experimental protocol identical to that in Fig. 5E Fig. 7B -C. Matrices underwent RNAi for MCPIP1 or p53 as described in the methods, and then lysates from 1-day released matrices underwent immunoprecipitation for MCPIP1 or p53, followed by immunoblotting for p53 or MCPIP1, respectively, as described in the Methods. Treatment with siRNA against either MCPIP1 or p53 markedly reduced/eliminated the ability of the immunoprecipitation procedure to pull down the p53 or MCPIP1, respectively, which suggested that the co-localization of MCPIP1 and p53 observed in (G) Migration of fibroblasts out of the nested FPCM. These images were intended as companion data to Figure 1A , and were included here to provide some larger images showing migration of the GFP-expressing fibroblasts in the nested FPCM model. Attached collagen matrices embedded with GFP-expressing human foreskin fibroblasts (Chao et al., 2014) were nested into acellular collagen matrices in the presence of serum, as described in the Methods. Fluorescent microscopic images were captured at 0, 12, and 24 h after nesting. Scale bar = 80 µm. 
Supplementary Materials and Methods

Reagents
Plasmid and siRNA transfection
The Flag-tagged MCPIP1 expression plasmid was generated by inserting the human MCPIP1 coding fragment into the pCMV-MAT- Tag® was generated by mutating K311C312 into GG using Flag-MCPIP1 as a template. Plasmid and siRNA transfection were performed on the FPCM model as previously described (Carlson et al., 2007) , with some modifications. siRNAs specific for p53 and MCPIP1 (pool of 3-4 unique siRNAs for each target) were obtained from Thermo Scientific Dharmacon RNAi Technologies (Accell SMART Pool). Flag/ Flag-MCPIP plasmids were transfected using DharmaFECT® 1 (Thermo Scientific) according to the manufacturer's protocol. Briefly, for a single collagen matrix, separate 17.5 µL aliquots of serum-free DMEM were combined with 3 µL of transfection reagent, 3 µL of siRNA stock (5 µM in water), or 1.5 µL of plasmid stock (200 ng/µL in water), and then incubated separately at room temperature (RT, c. 22˚C) for 15 min. These solutions (containing transfection reagent, siRNA, or plasmid) then were mixed together and incubated at RT for another 15 min. During this time, HFFs were prepared per the FPCM protocol at a concentration of 5.0 x 10 6 cells/mL in serum-free DMEM. Each transfection solution was mixed with 40 µL of this cell suspension, and this mixture was incubated at RT for 15 min. The cell-transfection solution then was added to the FPCM set-up process at the cell addition step per routine. After the collagen polymerization step, transfected matrices were cultured in serum-free DMEM for 24 h, and then the medium was replaced with 5% FBS in DMEM (supplemented with 50 µg/mL ascorbic acid). Matrices were incubated for an additional 48 h prior to initiating an experiment (i.e., matrix release). The transfection efficiency was determined 3 days after transfection with immunoblotting.
Nested matrix model and cell migration
The nested collagen matrix model was utilized as previously described (Chao et al., 2014; Grinnell et al., 2006; Miron-Mendoza et al., 2010) with some modifications; refer to
Supplementary Fig. S1A . For the nested attached matrix, a standard FPCM was incubated in the attached state for 72 h with 5% FBS in DMEM; the FPCM then was removed from the culture well, and placed onto a 60 µL aliquot of fresh acellular collagen matrix solution (neomatrix solution) that was centered inside a 12 mm-diameter score on the bottom of a new culture well. A 140 µL aliquot of neomatrix solution then was used to cover the newly-transferred FPCM. The neomatrix was allowed to polymerize for 1 h at 37˚C and 5% CO2, and then 2 mL of DMEM with 5% FBS was added to the well. The same procedure was followed for the nested released matrix, except that the initial incubation of the FPCM was 48 h in the attached stated, followed by detachment, and then 24 h incubation in the released state (see Supplementary Fig.   S1A ).
Cell migration out of the nested FPCM and into the acellular neomatrix was quantified 24 h after nesting with fluorescent microscopy. Digital images (constant dimension of 1000 × 800 µm) were captured with a EVOS® FL Cell Imaging microscope (Life Technologies, Grand Island, NY) from 3-5 randomly-selected microscopic fields at the interface of the nested FPCM with the acellular neomatrix (unfixed samples). Fibroblast migration out of the nested FPCM was quantified by counting the number of cells that had migrated clear from the nested matrix into the cell-free matrix. The number of cells that had migrated out of the nested matrix per field was averaged from these digital micrographs. All migration experiments were repeated in cells from five different donors.
In vitro scratch assay
Cell migration in a 2D culture system was evaluated using an in vitro scratch assay (Rodriguez-Menocal et al., 2012) . Briefly, GFP-HFFs were seeded into 24-well plates (1×10 5 cell/well) and cultured in 10% FBS in DMEM for 24 h, which resulted in confluence of ~70-80%.
Using a sterile 200 uL pipette tip, a line was scratched in the monolayer across the center of the well, keeping the pipette tip perpendicular to the plate. A second straight line then was scratched perpendicular to the first line to create a cross-shaped gap that was devoid of cells and about 800 µm wide. Each well was washed twice with 1 mL DMEM to remove any nonadherent cells, and then the well was filled with fresh 10% FBS in DMEM. Digital images of the cell gap were captured at set intervals, and the gap width was measured using ImageJ. Each experiment was repeated with three different cell strains.
Gel contraction assay
FPCM contraction was determined by the floating matrix contraction assay originally described by Bell et al. (Bell et al., 1979) , with minor modifications. Briefly, matrices were set up per the routine described above, allowed to polymerize, covered with 5% FBS in DMEM, and then were released from the culture well with a sterile spatula. Matrices were incubated at 37˚C
for a specified interval, and then fixed with 4% paraformaldehyde in PBS overnight at 4˚C. Fixed matrices were imaged with a desktop flatbed scanner. Matrix area subsequently was measured from the scans using ImageJ (http://rsb.info.nih.gov/ij/), and was expressed as a ratio of final (i.e., released) matrix area to initial (attached) matrix area.
Immunoblotting
Immunoblotting was utilized as previously described Carlson et al., 2013) , with minor modifications. FPCMs were collected from culture wells, washed with PBS, and the matrices were lysed using a Mammalian Cell Lysis kit (MCL1-1KT, Sigma-Aldrich®)
following the manufacturer's instructions. Briefly, two FPCMs to be extracted were transferred to a 1.5 mL microfuge tube containing 120 µL of ice-cold lysis buffer, and homogenized (50 strokes) using a polypropylene pestle (USA Scientific, Inc. Ocala, FL). Samples were clarified by centrifugation (20,000 g, 20 min, 4°C: Eppendorf 5417R centrifuge) , and the supernatant (100 µL) was transferred to a microfuge tube. The supernatant was mixed with 25 µL of 5x loading buffer (no. 161-0767; Bio-Rad; Hercules, CA) and boiled for 5 min. Sample were subjected to SDS-PAGE using 12% polyacrylamide gels, and transferred to PVDF membranes (Millipore).
Western blots were probed with primary antibodies overnight. Secondary antibodies were goat anti-mouse or -rabbit IgG conjugated to alkaline phosphatase (1:5,000). Signals were detected by chemiluminescence (SuperSignal West Dura Chemiluminescent Substrate, Thermo Scientific). Each Western blot was repeated using cells from three different donors. A single representative immunoblot for all related blots is shown in a given Figure. Immunoblot densitometry was performed using ImageJ (http://rsb.info.nih.gov/ij/) on scanned blot images.
Immunocytochemistry
Immunocytochemistry was performed as previously described (Carlson et al., 2007) , with some modifications. FPCMs were prepared as described above and cultured in 5% FBS in DMEM for 2 days. Attached or released matrices were fixed with 4% paraformaldehyde in PBS at 4˚C overnight. Fixed, intact matrices were permeabilized for 30 min at room temperature (RT) with 0.3% Triton X-100 in PBS. Permeabilized samples were blocked with 10% normal goat serum (NGS; Life Technologies) in 0.3% Triton X-100/PBS at RT for 2 h. Blocked samples were incubated with primary antibodies in 10% NGS/0.3%Triton X-100/PBS at 4°C overnight. The samples then were washed three times with PBS, and treated with donkey anti-rabbit (conjugated to Alexa-Fluor® 488) and donkey anti-mouse (conjugated to Alexa-Fluor® 576) secondary antibodies for 2 h at RT. After three PBS washes, samples were mounted with Prolong® Gold antifade reagent with DAPI (P36931; Life Technologies). Slides were examined with an EVOS FL fluorescence microscope.
Immunoprecipitation
The procedure for immunoprecipitation was performed as described by Peng et al. (Peng et al., 2008) Briefly, attached or released FPCMs were washed with PBS twice, followed by lysis in radioimmunoprecipitation assay (RIPA) buffer (50 mM Tris, pH8.0, 150mM NaCl, 0.1% SDS, 1.0% NP-40, and 0.5% sodium deoxycholate) containing proteinase and phosphatase inhibitors. For each sample, 200 μg protein was used for immunoprecipitation. The sample protein was incubated with 2 μg diluted p53 or MCPIP1 antibody overnight at 4°C, followed by incubation with 20 μL of protein A-sepharose (sc-2003, Santa Cruz) for 3 h at 4°C.
The mixture then was centrifuged at 6000 g for 30 s, the cell pellets were rinsed twice with RIPA buffer, and boiled in 2x immunoblot loading buffer for 4 min. After another spin at 6000 g for 30s, the supernatants were subjected to immunoblotting as described above for detection of MCPIP1 or p53.
Chromatin Immunoprecipitation (ChIP) Assay
The ChIP assay was performed according to the manufacturer's instructions EMD Millipore) . All materials were provided by the kit except as specified.
Briefly, 108 µL of 18.5% fresh formaldehyde was added directly into each well containing an FPCM (2 mL medium/well), yielding a final concentration of 1% formaldehyde. Fixation proceeded for 10 min at room temperature, followed by quenching with 10X glycine. The
FPCMs then were washed with 2 mL of ice-cold PBS containing the 1x protease inhibitor cocktail. The FPCMs were homogenized (50 strokes) using a polypropylene pestle in kit lysis buffer to harvest nuclei. DNA was sheared by sonication (5 sets of 10-s pulses on wet ice with The cross-linked protein/DNA complexes were reversed to free DNA by incubation at 62º C for 2 h, and then purified using DNA purification spin columns, following the manufacturer's instructions. Finally, the purified DNA was amplified via PCR (Chao et al., 2013) to identify the promoter region containing the NF-B binding site GGGGTTCCCC. The sequence of the primers used to identify the MCPIP1 promoter bound by NF-B was: anti-sense 5'-ACAGGCAGATAGATGGTGGG-3'; anti-sense 5'-TGTCTTCCGGCTCATGCTA-3'.
Computational prediction pipeline for NF-κB binding sites and primer design
In order to predict MCPIP1 promoter bound by transcription factor NF-κB (NF-κB miRNA target/binding sites), three publicly-available algorithms were used: TargetScan The GC content was set between 40 and 55%; the concentration of monovalent cation was set at 50 mM; the concentration of annealing oligos was set at 50 nM; and the maximum 3′ complementarity was set at 3.00.
Statistics
Data are expressed as mean ± s.e.m. Unpaired numerical data were compared using the unpaired t-test (two groups) or ANOVA (more than two groups), with statistical significance set at p < 0.05. This will be the FPCM solution; keep this on ice until step 17, in order to prevent premature polymerization of the collagen.
17. Warm the FPCM solution of step 16 in a 37˚C water bath for 4 min, with gentle swirling by hand. Do not let the tube sit idle during this 4 min period, but do not shake or otherwise over-agitate the tube; doing the latter will decrease cell viability.
18. Immediately after step 17, pipet 200 µL of collagen gel solution as a bead into the center of each inscribed circle of each well that will be utilized in the 24-well plate. The pipetted bead should expand to fill the 12 mm circle, but should retain an oblong bead shape. If the FPCM solution breaks outside of the circle, then that well will not be usable. Do step 18 quickly, until all wells have been pipetted, all the while swirling the FPCM solution frequently to keep cells from sinking to the bottom of the tube.
19. Without breaking the pipetted beads of the nascent collagen matrices, carefully place the 24-well plate into the 37˚C/5% CO2 incubator, and allow 1 hr for the collagen to polymerize.
20. Make vitamin C (ascorbic acid) solution while gels are polymerizing: 50 mg ascorbate acid (Sigma, Cat. No. A-4403) in 1 mL H2O, and passed through a 0.2 µM filter.
21. Also during the 1 hr collagen polymerization phase, make fresh growth medium: 5% FBS in DMEM, and add 1 µL of vitamin C stock (50 mg/mL) per mL of FBS/DMEM (final vit C concentration = 50 µg/mL).
22. After the collagen polymerization step, add 2-3 mL of fresh growth medium to each well.
23. Incubate at 37˚C/5% CO2 for ~48 h prior to beginning an experiment.
